The European Society of Cardiology meeting in Amsterdam produced some notable data for a slate of closely-watched heart drugs over the long weekend.
The recent, and very public, Chinese investigation into bribery allegations against GlaxoSmithKline and others has doctors running scared, making it tough for everyone to sell drugs there.
Novartis' Gilenya, which a consumer watchdog group last year pegged with safety concerns, is again being called into question after a patient taking the MS drug developed a rare brain infection.
Novartis has recalled 4.4 million bottles of its popular Maalox products due to manufacturing problems at its troubled U.S. OTC plant that predate CEO Joseph Jimenez's recent decision to strip the facility down to the most basic operations.
To win over U.K. cost-effectiveness gatekeepers, Novartis cut Afinitor's price. Unfortunately for the Swiss drugmaker, it didn't work. The National Institute for Health and Care Excellence still turned down a new use for the drug in HER2-negative breast cancer.
Bayer's Eylea has a new field for fighting Lucentis. The eye drug won a new approval in Europe, in patients with macular degeneration due to central retinal vein occlusion, setting it up for another market-share battle against Novartis.
Novartis' vaccine business was one of the problem areas awaiting Joerg Reinhardt when he took on the role of chairman earlier this month. The unit was the only part of the business to post a loss last quarter, and some investors continue to push for the sale of the operation.
Novartis has repeatedly had to deal with issues at its over-the-counter operation in Lincoln, NE, and once again has been bitten by problems there. This time, the company is recalling more than 4.4 million bottles of Maalox from the U.S. and Canada because of problems with packaging.
Novartis CEO Joe Jimenez wrote to Indian Commerce and Industry Minister Anand Sharma, accusing the government of favoring domestic companies over multinationals in its patent regime. Now, Indian Commerce Secretary S.R. Rao has fired back.
In an interview with the Financial Times, Vasella argued that the board's demands for a stringent noncompete clause amounted to "a prohibition to exert my profession."